Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Executive summary

Conclusions

1 evidence topic · 21 sources

Summary

Darovasertib is an investigational product, studied in combination with crizotinib in first-line HLA-A∗02:01-negative metastatic uveal melanoma. In the third quarter of 2026, IDEAYA submitted a new drug application for the combination under the FDA Real-Time Oncology Review (RTOR) program; no FDA acceptance of the application or action date was found. The FDA designated darovasertib an orphan drug for uveal melanoma in April 2022 and granted Fast Track designation to the combination in November 2022. IDEAYA states that the progression-free survival (PFS) data from OptimUM-02 may enable an accelerated approval filing, that overall survival (OS) data will support a potential full approval, and that an OS update is expected with the prespecified interim analysis in mid-2027.

OptimUM-02 is an open-label phase 2/3 trial in which 313 HLA-A∗02:01-negative participants without prior systemic therapy were randomized 2:1 to darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily or investigator's choice; ipilimumab plus nivolumab was selected for 79 control participants and pembrolizumab for 24, and none received dacarbazine. At a median follow-up of 7.4 months, median PFS by blinded independent central review (BICR) was 6.9 months with the combination and 3.1 months with investigator's choice (hazard ratio 0.42; 95% CI, 0.30 to 0.59), and the objective response rate by BICR was 37.1% (78 of 210) and 5.8% (6 of 103). Grade 3 or 4 treatment-related adverse events occurred in 40.6% (97 of 239) and 37.0% (37 of 100) of participants. Diarrhea was the most common treatment-related adverse event with the combination (203 participants, 84.9%); treatment-related adverse events led to withdrawal of darovasertib in 6 participants (2.5%) and of crizotinib in 24 (10.0%), and to dose reduction of darovasertib in 56 (23.4%) and of crizotinib in 63 (26.4%). OS data were immature at the cutoff, with an early trend favoring the combination, and no OS estimate has been reported; the quarterly report for the first quarter of 2026 describes a statistically significant improvement in the OS rate. Quality of life by the EORTC QLQ-C30 was a stated endpoint, and “quality-of-life data were not presented” at the ASCO 2026 presentation.

Evidence in HLA-A∗02:01-positive disease comes from OptimUM-01, an open-label, single-arm study. In its phase 2 expansion of 101 HLA-A∗02:01-positive participants, the confirmed objective response rate was 36.4% (4 of 11) in treatment-naive participants and 22.1% (19 of 86) overall, and 35.7% after prior tebentafusp; median PFS was 7.4 and 5.4 months in the treatment-naive and overall populations.

No price for darovasertib has been published. The regimen adds darovasertib to crizotinib, listed at $23,773.10 per 60 capsules. The first-line comparators in OptimUM-02 include pembrolizumab, listed at $12,517.44 per 3-week dose; tebentafusp, used in HLA-A∗02:01-positive disease, is listed at $22,050.00 per vial, and published cost-effectiveness analyses of tebentafusp report incremental cost-effectiveness ratios of $953,230 per QALY from a U.S. payer perspective and $728,513 per QALY gained at the sponsor-submitted price in the CADTH review.